AstraZeneca And Daiichi Sankyo Dose First Patient In Phase 3 TROPION-Urothelial04 Trial Of Datroway In Muscle-Invasive Urothelial Cancer
The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy
AstraZeneca started testing a new cancer medicine called Datroway in a big group of patients to see if it works better than current treatments. When a company moves a medicine into this stage of testing, it means the company thinks it's ready—watch to see if the results later show it actually helps patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.